CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2013-08-07): Everolimus shows no survival benefit in liver cancer

Drug & Device Development

Everolimus shows no survival benefit in liver cancer

Last Updated: 2013-08-07 12:00:05 -0400 (Reuters Health)

ZURICH (Reuters) - Swiss drugmaker Novartis said on Wednesday its drug Afinitor (everolimus) did not show a survival benefit in patients with advanced liver cancer.

Data from a late-stage trial found that Afinitor did not extend overall survival compared with placebo in patients with locally advanced or metastatic hepatocellular carcinoma (HCC), the most common type of liver cancer.

The study was examining the efficacy and safety of Afinitor in patients whose disease had progressed after treatment with or were intolerant to Onyx and Bayer's drug Nexavar (sorafenib).

"While we are disappointed with these results, Novartis remains committed to studying everolimus through a robust research and development program to address unmet needs in different types of cancer," said Alessandro Riva, Global Head of Oncology Development & Medical Affairs at Novartis Oncology.

Novartis is also conducting trials for Afinitor in gastrointestinal and lung neuroendocrine tumors, HER2-positive breast cancer, lymphoma and tuberous sclerosis complex, a rare genetic disease that causes tumors to grow in the brain and other vital organs. Results are expected in 2014 and 2015.

The drug is already approved for the treatment of advanced renal cell carcinoma and advanced pancreatic neuroendocrine tumors and advanced hormone-receptor positive, HER2-negative breast cancer.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.